Vesugen Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Vesugen dosing — protocols, safety, and where to buy.
Dose Range
10 mg oral capsule, 1-2 daily for 10-30 days
Dosage Calculator
Calculate exact dosing for Vesugen.
Dosing Protocols
A beginner Vesugen protocol assumes the user has not yet completed a formal cardiovascular risk assessment. Before any Vesugen cycle, do the following baseline workup:
Blood pressure: two weeks of home blood pressure readings, twice daily (morning and evening), at least five minutes of rest before reading, correct cuff size, arm supported at heart level. Average the readings. Target is under 130/80 for most adults; under 125/75 for patients with diabetes, CKD, or prior cardiovascular events.
Lipid panel: fasting total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C, and apolipoprotein B if available. Calculate 10-year ASCVD risk with the PCE (Pooled Cohort Equations) or similar calculator. Discuss statin indication with a primary care physician if 10-year risk is 7.5 percent or higher, or if LDL-C is 190 mg/dL or higher, or if established ASCVD is present.
Glucose metabolism: fasting glucose, HbA1c, and fasting insulin. Consider oral glucose tolerance testing if glucose is 100 to 125 mg/dL or HbA1c is 5.7 to 6.4 percent to distinguish prediabetes patterns.
Kidney function: BUN, creatinine, eGFR, urine albumin-creatinine ratio. Albuminuria is an independent marker of vascular risk that is often missed.
Liver function: AST, ALT, alkaline phosphatase, bilirubin. Baseline LFTs matter before starting any supplement or medication that might affect the liver.
CBC with differential: baseline red and white cell counts, hemoglobin, platelets.
TSH: thyroid dysfunction contributes to lipid abnormalities and should be corrected before attributing any lipid changes to a supplement.
With this baseline in hand, the beginner Vesugen cycle is: 1 capsule (20 mg nominal, approximately 2 to 4 mg peptide) on an empty stomach each morning with water for 10 consecutive days. Wait 60 to 90 days without peptide use. Then optionally repeat, up to two cycles in the first year.
During the 10-day cycle, measure home blood pressure twice daily and log. Record resting heart rate on rising, subjective energy (1 to 10), exercise tolerance, and any symptoms of concern (lightheadedness on standing, headache, bleeding, unusual bruising).
Repeat labs (lipid panel, HbA1c, kidney function, liver function) three months after the first cycle. Compare to baseline. A meaningful biochemical response to Vesugen alone would be a modest change in markers that does not overlap with the effect size of concurrent lifestyle changes. Realistically, if the user is also exercising more, eating better, and losing weight, attribution to Vesugen is difficult.
Beginner users should not combine Vesugen with new antihypertensive medications, new statins, or new PDE5 inhibitors started at the same time as the Vesugen cycle. Run Vesugen as a solo experiment on a stable existing regimen so any observed changes can be interpreted.
Do not use Vesugen as a substitute for starting indicated statin, antihypertensive, or antiplatelet therapy. If a primary care physician recommends these based on your risk, start the medications and consider Vesugen as a layered adjunct later.
Do not use Vesugen during pregnancy, during breastfeeding, during acute illness, or in the week before or after any scheduled surgical procedure.
Stop the cycle immediately and seek medical attention if any of the following occur: severe headache, chest pain, new shortness of breath, new leg swelling, sudden unilateral weakness or speech change (stroke symptoms), severe lightheadedness or syncope, or signs of bleeding (blood in urine, stool, or sputum; unusual bruising; prolonged bleeding). These are not expected effects of Vesugen but should trigger evaluation if they do occur.
An intermediate Vesugen protocol assumes the user has completed a baseline cardiovascular risk assessment, has at least one conservative cycle behind them with documented home blood pressure logs and lab comparison, has tolerated the peptide, and is working with a primary care physician or cardiologist who is aware of and supportive of the experimentation.
Intermediate cycle: 2 capsules (40 mg nominal, approximately 4 to 8 mg peptide) daily, split morning and early afternoon on an empty stomach, for 10 consecutive days. Wait 60 to 90 days. Repeat up to three times per year.
During each 10-day cycle, continue home blood pressure logs, resting heart rate logs, and symptom tracking. If available, measure HRV (heart rate variability) via a reliable device, and resting morning cortisol via hair or salivary assay for users interested in a broader stress/vascular measure.
Between cycles, maintain an evidence-graded baseline vascular support stack. That baseline includes:
Core supplements: omega-3 EPA+DHA 2 to 4 g daily (triglyceride reduction, cardiovascular protection); magnesium glycinate 300 to 400 mg at bedtime (blood pressure, sleep); vitamin D dosed to reach 40 to 60 ng/mL serum (typically 2000 to 5000 IU daily); vitamin K2 MK-7 90 to 180 mcg daily (vascular calcification concerns); CoQ10 100 to 200 mg daily (mitochondrial and endothelial support, may offset statin-associated myalgia).
Nitric oxide support (for those specifically interested in endothelial function beyond Vesugen cycling): L-citrulline 3 to 6 g daily or L-arginine 3 to 6 g daily, split across two doses.
Metabolic support: creatine monohydrate 5 g daily (muscle, possibly vascular/cognitive secondary benefits).
Diet emphasis: Mediterranean or DASH pattern, with specific attention to potassium-rich foods (leafy greens, beans, fruit), polyphenol-rich foods (berries, dark chocolate, extra virgin olive oil, green tea), fatty fish twice weekly, and sodium under 2300 mg per day.
Exercise emphasis: at least 150 minutes per week of moderate aerobic training, plus two to three resistance sessions per week, plus one weekly VO2max interval session if tolerated.
The intermediate user may layer additional Khavinson peptides across cycles. A common rotation: Cycle 1 Vesugen; Cycle 2 Cardiogen; Cycle 3 Pinealon; Cycle 4 Epitalon. This distributes bioregulator exposure across four cardinal axes (vascular, cardiac, neurological, pineal) over the course of a year.
Monitoring during intermediate phase: lipid panel and HbA1c every 6 months, kidney function and liver function annually, home blood pressure continuously, resting heart rate continuously. If on statin therapy, follow LFTs and CK per standard statin-monitoring practice. If on antihypertensive therapy, follow kidney function and electrolytes per standard practice.
If an intermediate user is producing a detectable biochemical response to cycling (modest blood pressure change, modest lipid change, modest HRV improvement) and no adverse signals, continuation with annual reassessment is reasonable. If no detectable response emerges across three full cycles with adequate measurement, the honest move is to stop Vesugen cycling and redirect to higher-evidence interventions or other experimental adjuncts.
Intermediate users on multi-drug cardiovascular regimens should pay particular attention to orthostatic blood pressure (lying, then standing after 1 and 3 minutes) during the first few days of a cycle. A drop of 20 mmHg systolic or 10 mmHg diastolic on standing is orthostatic hypotension and warrants evaluation and cycle cessation.
Intermediate users considering injectable rather than oral Vesugen should understand that the injectable route is research-chemical territory with meaningful additional risks (sterile technique, product quality, dose uncertainty). The evidence base does not support injectable Vesugen as superior to oral in any outcome a user can measure. The conservative recommendation remains oral capsule use.
An advanced Vesugen protocol is appropriate only for users who have multiple documented cycles behind them, stable labs, a working clinician relationship, and a clear self-experimental goal. Most users do not need an advanced protocol. The incremental benefit over intermediate cycling is small and the complexity of interpretation rises sharply.
Advanced cycle: 2 to 3 capsules daily (40 to 60 mg nominal, approximately 4 to 12 mg peptide), split across morning and afternoon, for 10 consecutive days. Wait 60 to 90 days. Up to four cycles per year.
Advanced users sometimes run multi-peptide Khavinson stacks within a single cycle — for example Vesugen plus Cardiogen, or Vesugen plus Pinealon, or a three-peptide combination of Vesugen, Cardiogen, and Epitalon. This is self-experimental. No randomized trial evidence supports multi-peptide stacking over single-peptide cycling.
At the advanced level, the user should have defined thresholds for whether Vesugen is generating enough benefit to continue. Realistic thresholds: a reproducible modest blood pressure reduction (3 to 6 mmHg systolic) across cycles that is not explained by concurrent lifestyle changes; a reproducible modest HRV improvement; a reproducible subjective improvement in symptoms relevant to the user's cardiovascular concern; and no safety signals on labs, blood pressure, or symptoms.
If these thresholds are missed, the advanced user should stop cycling and reconsider the evidence-based alternatives. For many users at an advanced stage of self-experimentation, the highest-impact intervention available is to optimize the mainstream pharmacological regimen — add ezetimibe, start a PCSK9 inhibitor, add an SGLT2 inhibitor, start a GLP-1 agonist, intensify antihypertensive therapy to hit a blood pressure target under 125/75, or start aspirin in the appropriate secondary prevention setting. Each of these is likely to produce more measurable benefit than continued Vesugen cycling.
Advanced users pairing Vesugen with ezetimibe, PCSK9 inhibitors, SGLT2 inhibitors, or GLP-1 agonists should understand that the pharmacological agents are doing essentially all the work in any measurable outcome. Vesugen is a bystander in that context. Continuing to cycle Vesugen alongside is harmless but does not add trial-evidence signal.
Advanced users on anticoagulation therapy (warfarin, DOACs) should consult with their cardiologist or hematologist before cycling Vesugen. The theoretical concern about additive effects on platelet function or vascular tone is poorly characterized, and the consequences of a bleeding event in an anticoagulated patient are significant.
Advanced users who are also considering testosterone replacement therapy, GLP-1 agonist use, SGLT2 initiation, or other significant pharmacological decisions should prioritize those decisions with their clinicians and not conflate them with Vesugen experimentation. Cycling Vesugen at the same time as starting semaglutide, for example, makes attribution of any observed change to either intervention essentially impossible.
Monitoring at advanced level: lipid panel every 3 to 4 months, HbA1c every 6 months, kidney and liver function every 6 months, home blood pressure continuously, resting heart rate continuously, HRV continuously if possible. Consider coronary artery calcium score at age-appropriate intervals (typically once at age 45 to 55 for primary prevention risk stratification, repeat in 5 years if indicated). Consider carotid intima-media thickness measurement or carotid plaque imaging every 2 to 3 years in users with elevated ASCVD risk. Consider peripheral arterial disease screening (ankle-brachial index) in users with symptoms or risk factors.
Advanced users should maintain an annual comprehensive cardiovascular risk review with their primary care physician or cardiologist. The bioregulator context can be part of that discussion. The review should explicitly answer: is the user's 10-year ASCVD risk at an appropriate level given interventions; are blood pressure and lipid targets being met; is there any new symptom or finding warranting further evaluation; is the current medication regimen appropriate; does the patient want to continue bioregulator cycling alongside.
The strongest answer at every advanced level remains: evidence-based pharmacology, evidence-based lifestyle, evidence-based preventive screening, and a strong clinician relationship — and then, optionally, Vesugen as a layered adjunct for users who want to explore the Khavinson framework. Vesugen is not a sufficient vascular health strategy. It is at best a minor complement to a real strategy.
Commonly Stacked With
Vesugen stacking decisions depend entirely on the user's cardiovascular goal. The first question is always: is the user's evidence-based foundation in place? The evidence-based foundation for vascular health looks like this:
Lifestyle: aerobic exercise 150+ minutes per week at moderate intensity or 75+ minutes per week at vigorous intensity; resistance training two to three sessions per week; Mediterranean or DASH dietary pattern; sodium restriction (under 2300 mg per day, ideally under 1500); body weight at a waist circumference under 40 inches for men, under 35 inches for women; seven to nine hours of sleep; smoking cessation; alcohol under 1 to 2 standard drinks per day for men, 0 to 1 for women.
Pharmacology (indication-dependent): statin therapy calibrated to ASCVD risk (often atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg for secondary prevention; lower-intensity for primary prevention); ezetimibe 10 mg daily as add-on when LDL-C targets require further reduction; PCSK9 inhibitor (evolocumab or alirocumab) for secondary prevention patients not at goal on maximally tolerated statin plus ezetimibe; ACE inhibitor or ARB for hypertension with secondary benefits for endothelial protection; dihydropyridine calcium channel blocker (amlodipine) for hypertension when ACE/ARB is not sufficient or tolerated; thiazide diuretic (chlorthalidone or hydrochlorothiazide) for hypertension; beta-blocker post-MI or in heart failure; SGLT2 inhibitor (empagliflozin, dapagliflozin) for diabetes, heart failure, or CKD; GLP-1 agonist (semaglutide, tirzepatide) for diabetes or obesity with ASCVD risk; aspirin 81 mg daily for secondary prevention; P2Y12 inhibitor (clopidogrel, ticagrelor) in addition post-stent.
Preventive screening: lipid panel every 4 to 5 years in low-risk adults, more frequently with treatment or risk factors; blood pressure at every clinic visit; HbA1c annually; kidney function annually; coronary artery calcium score in selected primary prevention patients to refine risk; carotid ultrasound for intima-media thickness or plaque detection in selected cases.
Clinical relationship: primary care for annual preventive visits and medication management; cardiology consultation when risk is elevated or complications develop.
That is the real cardiovascular prevention plan. Vesugen does not substitute for any part of it. Vesugen can be considered as an optional experimental adjunct for users who want to explore bioregulator-class peptides on top of an otherwise solid plan.
For users whose goal is general vascular aging support with otherwise low cardiovascular risk, a standard Vesugen cycle (1 to 2 capsules daily for 10 days, twice per year) layered onto lifestyle optimization is a reasonable low-stakes experiment. Track blood pressure, resting heart rate, HRV, and subjective markers (energy, exercise tolerance, temperature of extremities) before, during, and after cycling. If no reproducible objective change emerges across two or three cycles, the honest conclusion is that Vesugen is not meaningfully contributing for this user.
For users with diagnosed hypertension, the first priority is adequate pharmacological control (target under 130/80 for most, under 125/75 for some high-risk patients). Vesugen layered on top should be accompanied by home blood pressure monitoring to detect additive hypotension, particularly if the user is on multi-drug regimens.
For users with diagnosed hyperlipidemia or established atherosclerotic cardiovascular disease, the first priority is aggressive LDL-C reduction (target often under 70 mg/dL for secondary prevention). Vesugen adds nothing to the lipid reduction achievable with statins and ezetimibe. It can be layered as an experimental adjunct for endothelial function support, but it will not substitute for a statin in any meaningful cardiovascular outcome sense.
For users with diabetes, the first priority is glucose control (HbA1c under 7.0 percent for most), blood pressure control, statin therapy, and an SGLT2 inhibitor or GLP-1 agonist with cardiovascular benefit data in diabetes. Vesugen can be a layered experiment; it does not replace these foundations.
Cross-family stacking within the Khavinson catalog: Vesugen pairs conceptually with Cardiogen for users interested in combined vascular and myocardial bioregulator support. It pairs with Pinealon for users concerned about vascular cognitive impairment, given the vascular contribution to dementia risk. It pairs with Epitalon in a generalized longevity rotation. It pairs with Prostamax and Testagen for older men concerned about genitourinary-vascular overlap (erectile function, BPH-related vascular changes). None of these combinations has trial-level evidence. All are self-experiments.
Stacking with non-Khavinson vascular-supportive compounds: L-citrulline 3 to 6 g daily supports NO-dependent vasodilation with better evidence than Vesugen. L-arginine 3 to 6 g daily is the classical NO precursor with mixed cardiovascular trial data. Beetroot juice or nitrate supplements have modest evidence for blood pressure reduction. Omega-3 EPA+DHA 2 to 4 g daily has Cochrane-level support for triglyceride reduction and modest cardiovascular protection. CoQ10 100 to 200 mg daily may partially offset statin-associated myalgia. Vitamin K2 MK-7 90 to 180 mcg daily is sometimes used for vascular calcification concerns; evidence is suggestive rather than definitive. Nattokinase 2000 FU daily is popular but has weak human outcome data. Policosanol has mixed lipid evidence. Berberine 500 mg twice to three times daily has modest evidence for lipid and glucose reduction.
For erectile function with a vascular contribution, the evidence-based hierarchy is: PDE5 inhibitors (tadalafil 5 mg daily or on-demand sildenafil) as first-line, L-citrulline and lifestyle optimization as adjuncts, and Vesugen or other peptides as optional experimental additions. Caution on combining Vesugen with PDE5 inhibitors given the theoretical NO overlap.
For peripheral arterial disease, the evidence-based hierarchy is: smoking cessation, supervised exercise therapy, statin, antiplatelet, cilostazol for claudication, and revascularization for critical limb ischemia. Vesugen has no established role. It should not delay or substitute for any of the above.
A user who stacks Vesugen with multiple evidence-based interventions will see benefit, but the benefit is almost entirely attributable to the evidence-based interventions. Attribution of benefit to Vesugen specifically requires on-and-off comparisons across multiple cycles with careful measurement.
Side Effects & Safety
Contraindications
Absolute contraindications to Vesugen include pregnancy, breastfeeding, known hypersensitivity to short-peptide bioregulators or to the capsule excipients (milk-protein isolates, starch), active critical illness where introducing an uncharacterized variable would complicate care, and the week before and after any scheduled surgical procedure requiring attention to hemostasis. Any of these is a reason not to start Vesugen. Relative contraindications — reasons to defer Vesugen until the issue is clarified — include: symptomatic orthostatic hypotension under current medications; recent stroke (within 3 months) pending stable cardiovascular therapy optimization; recent myocardial infarction (within 3 months) pending cardiac rehabilitation and stable therapy; decompensated heart failure; active bleeding or severe thrombocytopenia; active peptic ulcer disease; severe uncontrolled hypertension (above 180/110) pending pharmacological control; severe uncontrolled hyperlipidemia (LDL-C above 190 mg/dL) pending statin initiation; severe chronic kidney disease (eGFR below 30); advanced liver disease (cirrhosis with decompensation). Age considerations: Vesugen is intended for adults with age-related vascular concerns. It is not intended for children or adolescents. Younger adults (under 40) without specific indications should pursue standard cardiovascular risk assessment rather than self-administer bioregulator peptides. Cardiovascular disease: Vesugen has no documented acute cardiovascular destabilization signal, but any vascularly active compound should be treated with caution in unstable cardiovascular conditions. Unstable angina, decompensated heart failure, recent major cardiovascular event, and uncontrolled arrhythmia are settings in which the user should defer Vesugen and prioritize optimization of evidence-based therapy with a cardiologist. Thromboembolic disease: users with a history of deep venous thrombosis, pulmonary embolism, atrial fibrillation on anticoagulation, or mechanical heart valve on anticoagulation should not initiate Vesugen without their cardiologist's input. The theoretical effect on coagulation and platelet function is uncharacterized and adds uncertainty to the bleeding-thrombosis balance these patients are actively managing. Bleeding history: users with a history of significant gastrointestinal bleeding, hemorrhagic stroke, or inherited bleeding disorder should not use Vesugen. Liver disease: Child-Pugh class B or C cirrhosis is a contraindication. Earlier stage liver disease is a relative contraindication pending clinician review. Kidney disease: eGFR below 30 mL/min/1.73m² is a relative contraindication. Bilateral renal artery stenosis is a specific concern given the vascular action claim and possible effect on renal perfusion. Endocrine disease: active pheochromocytoma is a specific relative contraindication given the unpredictable interactions between catecholamine excess and vasodilator effects. Untreated severe hypothyroidism is best corrected first because it contributes to lipid abnormalities and may be mistaken for Vesugen non-response. Active infection: defer Vesugen during acute systemic infection, particularly sepsis or severe COVID-19, where hemodynamic instability is a concern and where adding an uncharacterized variable complicates interpretation. Drug interactions: - Antihypertensives (ACE inhibitors, ARBs, calcium channel blockers, beta-blockers, diuretics): theoretical additive hypotensive effect. Use home blood pressure monitoring. - Statins: no known interaction. Standard statin monitoring (LFTs, CK if symptomatic) continues as normal. - Ezetimibe: no known interaction. - PCSK9 inhibitors: no known interaction. - SGLT2 inhibitors: no known interaction. - GLP-1 agonists: no known interaction. - Antiplatelets (aspirin, clopidogrel, ticagrelor, prasugrel): theoretical additive platelet inhibition. Monitor for bleeding signs. - Anticoagulants (warfarin, apixaban, rivaroxaban, dabigatran, edoxaban): theoretical concern about vascular tone and platelet function. Discuss with hematology or cardiology. - PDE5 inhibitors (tadalafil, sildenafil, vardenafil): theoretical additive NO-mediated hypotension. Caution with combined use; separate dosing and monitor blood pressure. - Alpha-blockers (tamsulosin, doxazosin): orthostatic risk; caution with combined use. - Nitrates (nitroglycerin, isosorbide mononitrate): specific theoretical overlap with any NO donor. Caution with combined use; avoid high-dose nitrate during Vesugen cycle. - Methylene blue, MAO inhibitors: not relevant to vascular interaction but generally cautious when combining multiple bioactive compounds. Pregnancy and breastfeeding: Vesugen is not recommended. The data for peptide bioregulators in pregnancy are essentially absent, and prudent avoidance is the default. Surgery and perioperative period: stop Vesugen at least 1 week before any scheduled surgery and do not resume until at least 1 week after, or longer based on surgeon's guidance. The theoretical effects on platelet function and vessel tone could complicate perioperative hemodynamics and hemostasis. Anesthesia: anesthesiologists should be informed about all supplements and peptides a patient is using. Vesugen should be included in the preoperative medication review. Imaging and procedures: Vesugen has no known interaction with contrast imaging (iodinated or gadolinium), colonoscopy prep, endoscopy, or other routine procedures. Discontinuation during these procedures is not necessary but is a reasonable precaution in the immediate procedural window. Operating machinery, driving: no documented cognitive or reaction-time effect. Vesugen is not expected to impair. Alcohol use: no direct interaction, but chronic heavy alcohol is an independent cardiovascular risk factor and works against any vascular health goal. Cannabis use: no specific data. Cannabinoids have complex cardiovascular effects (tachycardia, orthostasis at higher doses). Users heavy on cannabis with cardiovascular concerns have their own set of issues independent of Vesugen. Long-term use: no published data beyond a year or two of repeated cycling. A user who has been cycling Vesugen for multiple years without documented benefit should reconsider. A user who has been cycling with documented benefit should continue annual complete cardiovascular reviews.
Additional Notes
Commercial Vesugen capsules contain 20 mg of total powder per capsule, with approximately 2 to 4 mg of synthetic peptide and the balance as milk-protein and starch excipients. The 20 mg label refers to total powder, not peptide dose. This is consistent with the rest of the Khavinson oral bioregulator line.
Standard oral dosing in Khavinson-group observations has been 1 to 2 capsules daily for 10 consecutive days, cycled with a 60 to 90 day washout. Dose timing is typically morning on an empty stomach with water, 15 to 30 minutes before food. If a second capsule is taken, it is usually given in the early afternoon between meals.
There is no dose-ranging data to support advanced dosing above 2 capsules per day. Users cycling 3 or 4 capsules daily are operating beyond the published observational data. Empirical vendor forum reports suggest no consistent additional benefit at higher doses.
Injectable Vesugen is a research-chemical formulation distributed under research-use-only labeling. This is not the same as the commercial capsule. Users pursuing injectable dosing typically reconstitute lyophilized peptide with bacteriostatic water and administer 100 to 300 mcg subcutaneously daily during a 10 to 20 day cycle. Injectable protocols are less studied than oral cycling and carry additional risks (sterile technique, injection site reactions, dose uncertainty from research-chemical quality variability). The conservative recommendation remains oral capsule use for almost all users.
Cycling convention is 10-days-on / 60-to-90-days-off per the standard Khavinson framework. The rationale for this specific pattern is theoretical. There is no direct evidence comparing 10-day cycles with 20-day cycles, 30-day cycles, or continuous dosing. Most users do 2 to 4 cycles per year.
Dose for different cardiovascular goals (hypertension vs. lipid support vs. endothelial function) is not differentiated in published data. The same 1 to 2 capsules daily for 10 days is used regardless of goal.
Dose for users on existing cardiovascular medications: no established adjustment. Users on antihypertensives, statins, antiplatelets, or anticoagulants should follow the same 1 to 2 capsules daily for 10 days, with the caveat that home blood pressure monitoring becomes particularly important in those on multi-drug antihypertensive regimens.
Dose for users with chronic kidney disease, heart failure, or liver disease: defer Vesugen until stable with nephrology, cardiology, or hepatology input. The published data do not support dose adjustment guidance in these populations because the data do not exist.
Storage: capsules kept in a cool dry place out of direct sunlight. Refrigeration not required for sealed bottles but extends shelf life once opened. Shelf life typically 24 months from manufacture for sealed bottles. Discard if color, odor, or appearance change.
Missed doses during a cycle: skip the missed dose, resume next day. Do not double up. A cycle interrupted by more than two missed days is best terminated and restarted fresh after the standard washout.
Interaction with food: oral bioavailability is thought to be modestly better on an empty stomach. Taking with food reduces peak concentration but does not eliminate absorption.
Interaction with alcohol: no direct interaction data. A 10-day cycle is short enough that abstaining from alcohol is trivial. Chronic alcohol excess is an independent cardiovascular risk factor; a reader cycling Vesugen while drinking heavily is working against their own goal.
Dose for users over 70: not specifically studied. The same 1 to 2 capsules daily is used. Elderly users should pay additional attention to orthostatic blood pressure and drug interactions.
Dose for users under 40: not well studied. The Khavinson framework is oriented to age-related vascular decline in older adults. Younger adults with vascular concerns should pursue standard cardiovascular workup rather than self-administer Vesugen.
Dose for pregnancy or breastfeeding: not recommended. No data.
Timing with PDE5 inhibitors (tadalafil, sildenafil): the theoretical additive NO effect argues for caution. Separating Vesugen and PDE5i dosing by several hours is a reasonable precaution, as is measuring home blood pressure during any period of combined use.
Frequently Asked Questions
What is the recommended Vesugen dosage?
The typical dose range for Vesugen is 10 mg oral capsule, 1-2 daily for 10-30 days. Always start with the lowest effective dose.
How often should I take Vesugen?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Vesugen need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Vesugen side effects?
Published Khavinson-group observations describe Vesugen as well tolerated at the recommended oral dose of 1 to 2 capsules daily during a 10-day cycle. Specific adverse events noted include occasional mild gastrointestinal discomfort (nausea, loose stools) during the first days of a cycle, infrequent transient mild headache, and rare reports of skin flushing. Serious adverse events attributable to Vesugen are not documented in the published literature. That is a reassuring short-term safety profile, but the reader should understand the limits of the data. Most Vesugen studies are small cohorts with weeks-to-months follow-up and no placebo control. Rare serious adverse events — prothrombotic effect, bleeding, significant hypotension, liver or kidney injury — would require tens of thousands of patient-years of exposure to detect, which Vesugen has never accumulated in published form. "Well tolerated in small trials" is not the same as "safe for long-term unsupervised use." Theoretical concerns specific to Vesugen's proposed mechanism deserve explicit discussion. Additive hypotension is the first. If Vesugen produces modest eNOS-mediated vessel relaxation on top of existing antihypertensive therapy (ACE inhibitors, ARBs, calcium channel blockers, beta-blockers, diuretics), the combined effect could in theory produce blood pressure below the user's usual range, particularly at first morning standing (orthostatic hypotension). Users on multi-drug antihypertensive regimens should measure home blood pressure before and during a cycle and should be cautious with rapid positional changes. Symptoms of concern include lightheadedness on standing, near-fainting, or actual syncope. Any of these should prompt cycle cessation and evaluation. Additive antiplatelet effect is the second. Nitric oxide reduces platelet aggregation. Aspirin, clopidogrel, ticagrelor, and prasugrel all reduce platelet aggregation through different mechanisms. A user on one of these medications who adds Vesugen is layering effects. Clinically significant bleeding has not been reported with Vesugen, but the evidence gap is wide. Users on antiplatelets or anticoagulants should consult their cardiologist before starting Vesugen and should be aware of signs of occult bleeding (unusual bruising, prolonged bleeding from small cuts, blood in stool, dark tarry stools, unexplained fatigue suggesting anemia). Additive anticoagulant effect is the third. Warfarin, apixaban, rivaroxaban, dabigatran, and edoxaban all inhibit coagulation through specific mechanisms. Peptide effects on clotting factor levels and platelet activation are not characterized for Vesugen. A user on oral anticoagulation who adds Vesugen is operating beyond the published data. Hyperkalemia concern is theoretical. Some vasodilators (ACE inhibitors, ARBs) raise serum potassium modestly. If Vesugen acts on similar vascular-renal pathways, additive effects on potassium could occur. Users on potassium-sparing diuretics, ACE inhibitors, or ARBs should have baseline potassium and follow-up potassium during any new supplement addition. Renal perfusion concern is also theoretical. Short peptides that act on vascular tone could in principle alter renal perfusion pressure. In users with bilateral renal artery stenosis or advanced chronic kidney disease on ACE inhibitors or ARBs, this is a domain of legitimate caution. A renal function panel (BUN, creatinine, eGFR, electrolytes) before starting and six weeks after the first cycle is a reasonable precaution for users with preexisting CKD stage 3 or higher. Liver enzyme concern is not flagged in published Vesugen data but is worth a baseline LFT check alongside the other labs a user should have for any supplement trial in middle age. Allergic reactions to peptide therapeutics are rare but possible. Hives, itching, lip or tongue swelling, or breathing difficulty after a dose warrant immediate cessation and medical attention. The oral capsule excipient matrix includes milk-protein isolates and starch, which matter for patients with lactose intolerance or milk allergy. Headache and migraine: nitric oxide donors (nitroglycerin, isosorbide) are classical headache triggers in susceptible individuals. If Vesugen genuinely increases NO bioavailability, susceptible users may notice headache onset during cycling. Severe or prolonged headache should prompt cycle cessation and evaluation. Drug interaction data for Vesugen are effectively non-existent in the Western literature. Theoretical interactions of concern beyond those already discussed include: - PDE5 inhibitors (tadalafil, sildenafil, vardenafil): both PDE5 inhibitors and NO donors can synergistically drop blood pressure; the theoretical concern about Vesugen + PDE5i depends on whether Vesugen meaningfully raises NO. Caution is prudent. - Alpha-blockers (tamsulosin, doxazosin): used for BPH and hypertension, these are orthostatic risk medications; additive hypotension is possible. - Beta-blockers: no direct interaction expected but caution with bradycardia. - Sildenafil for pulmonary hypertension: dedicated caution with any additional vascular intervention. Long-term safety data beyond one year of repeated cycling do not exist in published form. The Khavinson framework recommends cycling (10 days on, 60 to 90 days off) as a safety feature, but the rationale for that specific pattern is theoretical rather than empirical. A reader using Vesugen for multiple years should revisit the decision annually based on continued benefit and safety labs. Pregnancy and breastfeeding: Vesugen is not recommended during pregnancy or breastfeeding. The data for peptide bioregulators in pregnancy are effectively non-existent, and the prudent default is avoidance. The most common real-world "side effect" of Vesugen use is opportunity cost. A user who buys Vesugen, does a cycle, notices modest or no objective change, and concludes "peptides don't work for me" has often bypassed the interventions with the strongest evidence — a formal cardiovascular risk assessment, lipid and blood pressure optimization, and evidence-based pharmacology. Framed that way, the worst side effect of Vesugen is that it can delay effective cardiovascular prevention. The right first step for a reader concerned about vascular health is a primary care or cardiology visit, not a Russian capsule.
Where can I buy Vesugen?
Visit our vendor directory to find trusted sources for Vesugen.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.